Actuate Therapeutics (NASDAQ:ACTU) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Actuate Therapeutics (NASDAQ:ACTU) from a hold rating to a sell rating in a report published on Saturday morning.

Other research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Actuate Therapeutics Price Performance

Shares of ACTU opened at $5.69 on Friday. Actuate Therapeutics has a 1-year low of $5.08 and a 1-year high of $11.99. The company has a market capitalization of $132.24 million, a P/E ratio of -6.54 and a beta of -0.15. The firm’s 50 day simple moving average is $6.51 and its 200 day simple moving average is $6.97.

Actuate Therapeutics (NASDAQ:ACTU) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02.

Insider Buying and Selling at Actuate Therapeutics

In related news, Director Todd S. Thomson sold 280,000 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $5.80, for a total transaction of $1,624,000.00. Following the completion of the sale, the director directly owned 904,795 shares in the company, valued at $5,247,811. This represents a 23.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 69.34% of the company’s stock.

Institutional Trading of Actuate Therapeutics

Institutional investors have recently made changes to their positions in the stock. Sfmg LLC increased its stake in shares of Actuate Therapeutics by 32.3% in the second quarter. Sfmg LLC now owns 14,550 shares of the company’s stock worth $89,000 after buying an additional 3,550 shares during the period. Bank of America Corp DE grew its holdings in Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after acquiring an additional 15,267 shares during the last quarter. New York State Common Retirement Fund bought a new stake in Actuate Therapeutics in the 2nd quarter worth $105,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Actuate Therapeutics by 492.6% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after acquiring an additional 15,393 shares during the period. Finally, Gleason Group Inc. bought a new position in shares of Actuate Therapeutics during the second quarter valued at about $116,000.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.